Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Medicine > 2025 Vol. 3 > No. 2 > 100129
Next Article Previous Article
COMMENTARY   Open Access     Cite

Inclusion of BiTEs as consolidation for MRD-negative ALL: Where are we now and where can we go?

  • 1.

    Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou 310000, China

  • 2.

    Institute of Hematology, Zhejiang University, Hangzhou 310000, China

  • 3.

    Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou 310000, China

  • 4.

    Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China

  • 5.

    Pediatric Cancer Research Center, National Clinical Research Center for Child Health, Hangzhou 310000, China

  • 6.

    These authors contributed equally

    • Show all affliationsShow less
More Information
  • Corresponding authors: mxd453@163.com (X.M.);  yanminzhao@zju.edu.cn (Y.Z.)
  • Received Date:  September 29, 2024
    Accepted Date:  April 23, 2025
    Published Online:  April 24, 2025
The Innovation Medicine  3(2),  https://doi.org/10.59717/j.xinn-med.2025.100129  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] Litzow M.R., Sun Z., Mattison R.J., et al. (2024). Blinatumomab for MRD-negative acute Lymphoblastic Leukemia in adults. N. Engl. J. Med. 391:320−333. DOI:10.1056/NEJMoa2312948

    View in Article CrossRef Google Scholar

    [2] Aldoss I., Song J., Stiller T., et al. (2017). Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am. J. Hematol. 92:858−865. DOI:10.1002/ajh.24783

    View in Article CrossRef Google Scholar Scopus

    [3] Feucht J., Kayser S., Gorodezki D., et al. (2016). T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget 7:76902−76919. DOI:10.18632/oncotarget.12357

    View in Article CrossRef Google Scholar Scopus

    [4] Foà R., Bassan R., Vitale A., et al. (2020). Dasatinib-blinatumomab for ph-positive acute lymphoblastic leukemia in adults. N. Engl. J. Med. 383:1613−1623. DOI:10.1056/NEJMoa2016272

    View in Article CrossRef Google Scholar Scopus

    [5] Zhang M., Hu Y., Wei G., et al. (2023). Dasatinib and CAR-T Cell therapy for newly diagnosed ph-positive acute lymphoblastic leukemia in adults. Blood 142:891. DOI:10.1182/blood-2023-186225

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    Zhang S., Wang Y., Xu X., et al. (2025). Inclusion of BiTEs as consolidation for MRD-negative ALL: Where are we now and where can we go? The Innovation Medicine 3:100129. https://doi.org/10.59717/j.xinn-med.2025.100129
    Zhang S., Wang Y., Xu X., et al. (2025). Inclusion of BiTEs as consolidation for MRD-negative ALL: Where are we now and where can we go? The Innovation Medicine 3:100129. https://doi.org/10.59717/j.xinn-med.2025.100129

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(2144) PDF downloads(1040)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.